1Dagmar Kubitza,Michael Becka,Georg Wensing,Barbara Voith,Michael Zuehlsdorf. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects[J] 2005,European Journal of Clinical Pharmacology(12):873～880
6Jafri SM.Hypercoagulability in heart failure[J].Semin Thromb Hemost,1997,23(6):543-545.
7McMurray JJ,Adamopoulos S,Anker SD.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2012,33(14):1787-1847.
8Gheorghiade M,Vaduqanathan M,Fonarow GC,et al.Anticoagulation in heart failure:current status and future direction[J].Heart Fail Rev,2013,18(6):797-813.
9Ahnert AM,Freudenberger RS.What do we know about anticoagulation in patients with heart failure[J].Curr Opin Cardiol,2008,23(3):228-232.
10Lip GY,Ponikowski P,Andreotti F,et al.Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm.A joint consensus documentfrom the ESC Heart Failure Association and the ESC Working Group on thrombosis[J].Eur J Heart Fail,2012,14(7):681-695.
